scispace - formally typeset
W

Wojciech Rzeski

Researcher at Maria Curie-Skłodowska University

Publications -  131
Citations -  3331

Wojciech Rzeski is an academic researcher from Maria Curie-Skłodowska University. The author has contributed to research in topics: Apoptosis & Cancer cell. The author has an hindex of 29, co-authored 127 publications receiving 2794 citations. Previous affiliations of Wojciech Rzeski include Medical University of Lublin.

Papers
More filters
Journal ArticleDOI

Expression of glutamate receptor subunits in human cancers.

TL;DR: It is revealed that glutamate receptor subunits are differentially expressed in human tumor cell lines at the mRNA and the protein level, and that their expression is associated with the formation of functional channels.
Journal ArticleDOI

Anticancer, neuroprotective activities and computational studies of 2-amino-1,3,4-thiadiazole based compound.

TL;DR: A prominent neuroprotective activity of FABT was observed in the neuronal cultures exposed to neurotoxic agents like serum deprivation and glutamate, and in anticancer concentrations it exerted a trophic effect in neuronal cell culture and had no influence on viability of normal cells including astrocytes, hepatocytes, and skin fibroblasts.
Journal ArticleDOI

Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain

TL;DR: It is shown that systemic administration of the NMDA receptor antagonist MK801 to 7-day-old rats leads to impaired activity of extracellular signal-regulated kinase 1/2 (ERK1/2) and reduces levels of phosphorylated cAMP-responsive element binding protein (CREB) in brain regions which display severe apoptotic neurodegeneration.
Journal ArticleDOI

Glutamate antagonists limit tumor growth.

TL;DR: It is demonstrated that glutamate antagonists inhibit proliferation of human tumor cells and suggest anticancer potential of glutamate antagonists.
Journal ArticleDOI

NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth

TL;DR: Dizocilpine inhibits the extracellular signal-regulated kinase 1/2 pathway, an intracellular signaling cascade that is activated by growth factors and controls the proliferation of cancer cells, and indicates that it may be useful in the therapy of human cancers.